U.S. hedge fund plans to take on big pharma ovoo er patents | Reuters
`
`EDITION:
`
`U.S.
`
`SIGN IN REGISTER
`
`Search Reuters
`
`HOME BUSINESS
`
`MARKETS
`
`WORLD
`
`POLITICS
`
`TECH
`
`OPINION
`
`BREAKINGVIEWS
`
`MONEY
`
`LIFE
`
`PICTURES
`
`VIDEO
`
`Funds | Wed Jan 7, 2015 12:59pm EST
`
`Related: REGULATORY NEWS, M&A, MARKETS, MUTUAL FUND CENTER
`
`U.S. hedge fund plans to take on big pharma over
`patents
`
`OSLO
`
`Jan 7 U.S. hedge fund manager Kyle Bass, who won fame for predicting the subprime
`
`REUTERS RECOMMENDS
`
`mortgage crisis in 2008, plans to take on some of the world's biggest drug producers by
`
`challenging the patents of their top brands, he said on Wednesday.
`
`Republican boogeyman
`
`WASHINGTON - With his bare-chested swagger and
`
`wily geopolitical moves, Republican presidential
`
`hopefuls are using Vladimir Putin to attack the
`
`Democrats on foreign policy. Full Article »
`
`Bass, the founder of Dallas-based Hayman Capital Management, L.P., said some drug
`
`firms were hanging onto patents in questionable ways and he planned to take around 15
`
`firms into a so called Inter Partes Review (IPR) process created by the America Invents
`
`Act. in 2012.
`
`"We are going to challenge and invalidate patents through the IPR process ... (and) we are
`
`not going to settle," Bass said in a presentation in Oslo, Norway's capital.
`
`"The companies that are expanding patents by simply changing the dosage or the way
`
`they are packaging something are going to get knee capped," he said.
`
`Bass said the firms he planned to challenge had a combined market capitalisation of $450
`
`billion and if he succeeded that could halve, benefitting his investments and reducing
`
`medicine prices in the United States.
`
`"This is going to lower drug prices for Medicare and for everyone," he said.
`
`Bass did not name any targets and also declined to elaborate on how he planned to make
`
`a financial gain from the challenges. He also declined to give details on his investment
`
`position.
`
`The Inter Partes Review was introduced by the U.S. government as a quicker and more
`
`effective method for challenging existing patents. (Reporting by Joachim Dagenborg,;
`
`Writing by Balazs Koranyi; Editing by Mark Potter)
`
`
`
`ADVERTISING
`
`htttt p://// w// ww.reuters.com/article/ee 2015/55 01/07/77 pharmaceuticals-haymancapital-idUSL3N0UM42O20150107
`
`1/3
`
`
`Page 1 of 3
`
`CELGENE EXHIBIT 2052
`Coalition for Affordable Drugs VI LLC (Petitioner) v. Celgene Corporation (Patent Owner)
`Case IPR2015-01103
`
`

`
`U.S. hedge fund plans to take on big pharma ovoo er patents | Reuters
`
`More From Reuters
`
`Sponsored Financial Content
`
` (?)
`
`7 Outrageous Credit Cards For Those Of Us
`That Have Excellent Credit Next Advisor
`
`Mutual fund vs. ETF: Which is right for you?
`Fidelity can help. Fidelity Investments
`
`How rising rates could impact 3 key sectors
` J.P. Morgan Funds
`
`One stock powers Apple's biggest hits, and
`it's just getting started The Fool
`
`Our expert panel discusses investing ideas
`for the rest of 2015. Fidelity InsideOut
`
`Biden chokes up as
`he goes toe to toe
`with Palin on family
`challenges | 31 May
`
`When the Supreme
`Court is this wrong,
`it’s time to overrule
`them | 2 Jun
`
`California woman
`missing for two
`weeks found alive in
`car, husband dead
`| 26 May
`
`Russian aircraft head
`off U.S. destroyer in
`Black Sea: RIA
`| 30 May
`
`German No 2 tells
`Greece that Europe
`has hit its limits
`| 6 Jun
`
`From The Web
`
`Sponsored Links
`
`by Taboola
`
`Living With Afib? 10 Treatments
`WebMD
`
`#1 reason not to buy a new
`computer
`SpeedFixTool
`
`These 5 Old Money Families Are
`No Longer Wealthy
`Bankrate
`
`Cable TV Is Dying. Here's What
`Comes Next
`The Motley Fool
`
`The Stunning Evolution of
`Millennials: They've Become th…
`The Huffington Post | Wealthfront
`
`How This Razor is Disrupting a
`$13 Billion Industry
`Dollar Shave Club
`
`Sponsored Topics
`
`1.
`
`Stocks to Invest in 2015
`
`6.
`
`Profitable Small Business Ideas
`
`2.
`
`Top 10 Retirement Plans
`
`7.
`
`Top Stock Picks
`
`3.
`
`Best CD Rates
`
`8.
`
`IRA Gold Investments
`
`4.
`
`Best Income Funds
`
`9.
`
`Reverse Mortgage Calculator
`
`5.
`
`High Yield Bonds
`
`10.
`
`Retirement Income Funds
`
`TRENDING ON REUTERS
`
`Plunged into uncertainty, Turkey could
`face early election |
`
`1
`
`Kurdish party thwarts Erdogan's
`
`ambitions with Turkish election advance | 2
`
`Escaped New York prisoners may have
`had help from staff: governor |
`
`German yields rise again, stocks dip
`
`White House denies Obama said strong
`dollar a problem
`
`3
`
`4
`
`5
`
`Sponsored Financial Content
`
` (?)
`
`Understanding the market's mispricing of key
`asset classes J.P. Morgan Funds
`
`Find out where investing professionals are
`looking for the rest of '15 Fidelity InsideOut
`
`7 Outrageous Credit Cards For Those Of Us
`That Have Excellent Credit Next Advisor
`
`CDs and short duration bonds: Get more
`yield on your cash. Fidelity Investments
`
`Investors are scooping up these 10 tiny
`gems. Free Report reveals why. Penny Stock
`Publishing
`
`PHOTOS OF THE DAY
`
`Our top news photos from the past 24 hours.
`
`Slideshow »
`
`Tony Awards red carpet
`
`Best of the Tony Awards
`
`American Pharoah wins Triple Crown
`
`Funeral for Beau Biden
`
`RECOMMENDED VIDEO
`
`The golden path to flashing cash in China
`
`Inspectors find ruptured California pipeline badly
`corroded
`
`Police and Nationalists clash in eastern Turkey
`
`More than 500 dead in brutal Indian heat wave
`
`htttt p://// w// ww.reuters.com/article/ee 2015/55 01/07/77 pharmaceuticals-haymancapital-idUSL3N0UM42O20150107
`
`2/22 3
`
`Page 2 of 3
`
`

`
`U.S. hedge fund plans to take on big pharma ovoo er patents | Reuters
`
`Sponsored Topics
`
`1.
`
`Top Stock Picks
`
`2.
`
`IRA Gold Investments
`
`3.
`
`Profitable Small Business Ideas
`
`4.
`
`Stocks to Invest in 2015
`
`5.
`
`High Yield Bonds
`
`6.
`
`Top 10 Retirement Plans
`
`Reuters.com
`
`Business Markets World
`
`Politics
`
`Technology
`
`Opinion Money
`
`Pictures
`
`Videos
`
`Site Index
`
`More from Reuters
`
`Reuters News Agency
`
`Brand Attribution Guidelines
`
`Delivery Options
`
`Support & Contact
`
`Support
`
`Corrections
`
`Account Information
`
`Register
`
`Sign In
`
`Connect with Reuters
`
`Twitter
`
`Facebook
`
`Linkedin
`
`RSS
`
`Podcast
`
`Newsletters
`
`Mobile
`
`About
`
`Privacy Policy
`
`Terms of Use
`
`Advertise With Us
`
`AdChoices
`
`Copyright
`
`Our Flagship financial
`information platform
`incorporating Reuters
`Insider
`
`An ultra-low latency
`infrastructure for
`electronic trading and
`data distribution
`
`A connected approach to
`governance, risk and
`compliance
`
`Our next generation legal
`research platform
`
`Our global tax
`workstation
`
`Back to top
`
`Thomsonreuters.com
`
`About Thomson Reuters
`
`Investor Relations
`
`Careers
`
`Contact Us
`
`Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal
`
`finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires
`
`fair presentation and disclosure of relevant interests.
`
`NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
`
`htttt p://// w// ww.reuters.com/article/ee 2015/55 01/07/77 pharmaceuticals-haymancapital-idUSL3N0UM42O20150107
`
`3/33 3
`
`Page 3 of 3